Loading stock data…
$6.49-0.03 (-0.46%)
Nutriband Inc.
Nutriband Inc. in the Healthcare sector is trading at $6.49 with a market capitalization of $99M. Wall Street consensus targets $15.00 (1 analysts), implying a +131.1% move over the next 12 months. The stock is currently 29% below its 52-week high of $9.19, remaining 52.0% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Total Revenue | $437,514↑ | $433,399↑ | $400,709↑ | $346,058↓ | $622,452 |
| Gross Profit | $181,874↓ | $196,801↑ | $88,941↑ | $68,505↓ | $156,881 |
| Operating Income | -$890,637↑ | -$1.25M↓ | -$1.02M↑ | -$3.88M↓ | -$2.00M |
| Net Income | -$880,561↑ | -$1.24M↓ | -$968,059↑ | -$3.87M↓ | -$2.00M |
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products in the United States. Its lead product is AVERSA Fentanyl, an abuse deterrent fentanyl patch for the treatment of chronic pain. The company also develops AVERSA buprenorphine ...